Abstract 250P
Background
It is widely believed that nutritional and psychological disorders can affect the outcome of cancer treatment and the life quality of patients. However, the importance of nutritional and psychological interventions is still underestimated, and cancer treatment remains the main focus of clinical practice. In order to raise awareness of clinicians, we conducted a survey of nutritional and psychological status of cancer patients.
Methods
From December 2020 to January 2022, 1000 patients with advanced cancer completed the online survey of stardard nutritional and psychological scales.
Results
All the patients had solid tumors, and most(84.1%) of them had trouble in life quality caused by cancer treatment. The survey indicated 74.7% of the patients had at least once nutritional risk. Psychological disorders referred to three terms including insomnia, anxiety and depression. Patients experienced mild, moderate and severe insomnia was respectively 48.2%, 18.5% and 1.5%; mild, moderate and severe anxiety was respectively 57.5%, 25.5% and 3.3%; mild, moderate and severe depression was respectively 20.7%, 9.5% and 2.3%. Surprising 92.7% of the patients had never received any nutritional or psychological intervention.
Conclusions
There is an urgent need to assess the nutritional and psychological status of cancer patients in the early stage of treatment, and implement effective interventions to enable more patients to live longer and better.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03